BrightPath Biotherapeutics Co., Ltd.

4594

JP3274140007

Biotechnology & Medical Research

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
59 ^JPY	0.00%		+5.36%	-32.18%

2023	BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	CI
2023	BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	CI

BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index

September 19, 2022 at 12:00 am EDT

Latest news about BrightPath Biotherapeutics Co., Ltd.

BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited	Nov. 29	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited	Nov. 13	CI
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index	22-09-19	CI
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine	22-04-13	MT
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment	22-04-13	MT
Brightpath Biotherapeutics Announces Preclinical Data on BP1209	22-04-12	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	22-01-31	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm	22-01-13	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	20-04-22	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	20-04-06	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	18-11-09	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018	18-08-10	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019	18-05-11	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	18-02-14	CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm	17-12-07	CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥12.17 million in funding from Credit Suisse Securities Limited, Investment Arm	17-11-21	CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018	17-11-10	CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-08-14	CI
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo	17-07-23	CI
GreenPeptide Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Earnings Guidance for the Year Ending March 31, 2018	17-05-12	CI
GreenPeptide Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2016, Provides Earnings Guidance for the Year Ending March 31, 2017	17-02-10	CI
GreenPeptide Co., Ltd. Announces Notice of Initiation of Phase II Clinical Trial of GRN-1201	17-01-27	CI
Advanced Immunotherapy Co., Ltd. announced that it has received funding from GreenPeptide Co., Ltd.	16-11-30	CI
Advanced Immunotherapy Co., Ltd. announced that it expects to receive funding from GreenPeptide Co., Ltd.	16-11-19	CI
GreenPeptide Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Earnings Guidance for the Year Ending March 31, 2017	16-11-11	CI

Chart BrightPath Biotherapeutics Co., Ltd.

Duration

Period

Chart BrightPath Biotherapeutics Co., Ltd.

More charts

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHTPATH BIOTHERAPEUTICS CO., LTD.	-32.18%	26.51M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research